Home » Stocks » AVEO

AVEO Pharmaceuticals, Inc. (AVEO)

Stock Price: $8.21 USD -0.08 (-0.97%)
Updated Jan 26, 2021 3:56 PM EST - Market open
Market Cap 238.83M
Revenue (ttm) 5.90M
Net Income (ttm) -28.54M
Shares Out 25.81M
EPS (ttm) -1.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $8.21
Previous Close $8.29
Change ($) -0.08
Change (%) -0.97%
Day's Open 8.25
Day's Range 8.06 - 8.39
Day's Volume 270,064
52-Week Range 2.60 - 9.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 6 days ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Her...

Other stocks mentioned: HTGC
Business Wire - 1 week ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), ...

Other stocks mentioned: AZN
Business Wire - 2 weeks ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today highlighted its recent progress and outlined its 2021 outlook. “We remain keenly focused on building out our commercial team ahead o...

Business Wire - 2 weeks ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conf...

Business Wire - 3 weeks ago

BOSTON, Mass.--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the 39th Annual J.P. Morgan Hea...

Seeking Alpha - 4 weeks ago

AVEO is preparing for the potential U.S. commercial launch for Tivozanib in R/R RCC. The FDA has set the PDUFA Date for March 31st, 2021.

Business Wire - 2 months ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Con...

Zacks Investment Research - 2 months ago

AVEO (AVEO) delivered earnings and revenue surprises of -37.50% and -5.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the third quarter ended September 30, 2020 and provided a business update. “In advance of the Food an...

Business Wire - 2 months ago

BOSTON & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced that previously reported results from the Phase 1b/2 TiNivo study of oral (PO) ...

Zacks Investment Research - 2 months ago

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 2 months ago

On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.

Business Wire - 3 months ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AV...

Zacks Investment Research - 4 months ago

AVEO Pharmaceuticals (AVEO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Business Wire - 4 months ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. TIV...

Zacks Investment Research - 4 months ago

As of late, it has definitely been a great time to be an investor AVEO Pharmaceuticals.

Zacks Investment Research - 4 months ago

AVEO reclaims complete rights to ficlatuzumab from Biodesix for an undisclosed sum. The candidate is being developed for several cancer indications.

Zacks Investment Research - 4 months ago

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 4 months ago

AVEO Pharmaceuticals (AVEO) seeks an FDA nod for Fotivda in the United States to treat relapsed or refractory RCC. A decision from the regulatory agency is expected on Mar 31, 2021.

Business Wire - 4 months ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody ...

Business Wire - 4 months ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conf...

Zacks Investment Research - 5 months ago

AVEO (AVEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 5 months ago

AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.

Zacks Investment Research - 5 months ago

AVEO (AVEO) delivered earnings and revenue surprises of 17.65% and -49.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the second quarter ended June 30, 2020 and provided a business update. “The first half of 2020 was on...

Zacks Investment Research - 5 months ago

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 5 months ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin).

Business Wire - 7 months ago

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includ...

Seeking Alpha - 7 months ago

Aveo Oncology: Managing A Position Following Positive ASCO Data Readout

Zacks Investment Research - 7 months ago

AVEO's new drug application submission for tivozanib as a treatment of relapsed or refractory renal cell carcinoma gets acceptance from the FDA. A decision is expected on Mar 31, 2021.

Zacks Investment Research - 7 months ago

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

Zacks Investment Research - 7 months ago

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 8 months ago

AVEO Pharmaceuticals (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

AVEO (AVEO) delivered earnings and revenue surprises of -4.00% and -65.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 9 months ago

AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.

Zacks Investment Research - 10 months ago

Even though AVEO Pharmaceuticals (AVEO) reports narrower-than-estimated loss in the fourth quarter, its revenues miss the mark.

Zacks Investment Research - 10 months ago

AVEO (AVEO) delivered earnings and revenue surprises of 51.72% and -63.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 11 months ago

AVEO (AVEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 11 months ago

AVEO: Still A Speculative Buy Ahead Of FOTIVDA NDA Submission

Zacks Investment Research - 11 months ago

AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.

Zacks Investment Research - 1 year ago

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

AVEO Pharmaceuticals (AVEO) rides high on both earnings and revenue beat in the third quarter. Shares rise.

Seeking Alpha - 1 year ago

AVEO Oncology recently announced that the FDA has once again recommended the company hold off on submitting FOTIVDA's NDA for RCC. AVEO intends to file NDA in Q1 of 2020.

Zacks Investment Research - 1 year ago

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

AVEO Oncology has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 1 year ago

AVEO (AVEO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 1 year ago

AVEO recently publicized the results of their interim analysis of FOTIVDA in advanced RCC. The company reported an improved OS HR ratio of 0.99.

Zacks Investment Research - 1 year ago

AVEO posts positive updated results from the second prespecified overall survival analysis of Fotivda for treating highly refractory metastatic renal cell carcinoma. Stock up more than 30%.

About AVEO

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination w... [Read more...]

Industry
Biotechnology
IPO Date
Mar 12, 2010
CEO
Michael Bailey
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
AVEO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for AVEO stock is "Strong Buy." The 12-month stock price forecast is 12.00, which is an increase of 46.16% from the latest price.

Price Target
$12.00
(46.16% upside)
Analyst Consensus: Strong Buy